Last reviewed · How we verify
RIFINAH ©
Rifinah is an antitubercular medication that works by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis.
Rifinah is an antitubercular medication that works by inhibiting the synthesis of mycolic acid in Mycobacterium tuberculosis. Used for Treatment of tuberculosis.
At a glance
| Generic name | RIFINAH © |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antitubercular |
| Target | RNA polymerase beta-subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Rifinah, a derivative of rifampicin, targets the beta-subunit of the bacterial RNA polymerase, preventing the transcription of essential genes in M. tuberculosis. This action ultimately leads to the inhibition of bacterial growth and replication.
Approved indications
- Treatment of tuberculosis
Common side effects
- Hepatotoxicity
- Thrombocytopenia
- Nephrotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RIFINAH © CI brief — competitive landscape report
- RIFINAH © updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI